Budget Impact Associated with the Introduction of the Impella 5.0® Mechanical Circulatory Support Device for Cardiogenic Shock in France.

Alexandre Le GuyaderMathieu Pernot Clément DelmasStéphane RozeIsabelle FauErwan FlecherGuillaume Lebreton

Published in: ClinicoEconomics and outcomes research : CEOR (2021)

The Impella 5.0 device was associated with cumulative cost savings in excess of EUR 4 million over a 5-year period compared with current practice. Projected savings were driven by a lower rate of device-related complications with Impella 5.0 compared with VA-ECMO.

Keyphrases

extracorporeal membrane oxygenation
acute respiratory distress syndrome
left ventricular assist device
healthcare
respiratory failure
climate change
risk factors
quality improvement
intensive care unit
drug induced